• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global Personalized Medicine Diagnostics Market 2012-2016 Product Image

Global Personalized Medicine Diagnostics Market 2012-2016

  • ID: 2617704
  • July 2013
  • Region: Global
  • 111 Pages
  • TechNavio

FEATURED COMPANIES

  • 20/20 GeneSystems Inc.
  • AltheaDx Inc.
  • BG Medicine Inc.
  • CombiMatrix Corp.
  • Genomic Health Inc.
  • MDxHealth SA
  • MORE

The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market.

The report, the Global Personalized Medicine Diagnostics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Personalized Medicine Diagnostics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG.

The other vendors mentioned READ MORE >

FEATURED COMPANIES

  • 20/20 GeneSystems Inc.
  • AltheaDx Inc.
  • BG Medicine Inc.
  • CombiMatrix Corp.
  • Genomic Health Inc.
  • MDxHealth SA
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Introduction
04. Market Research Methodology
Market Research Process
Research Design
Research Methodology
05. Scope of the Report
Market Overview
Product Offerings
06. Market Landscape
06.1 Market Size and Forecast
07. Key Market Segmentation
07.1 Global Personalized Medicine Diagnostics Market in Diabetes
Market Size and Forecast
Key Market Segmentation of Personalized Medicine Diagnostics in Diabetes
07.2 Global Personalized Medicine Diagnostics Market in Cancer
Market Size and Forecast
Key Market Segmentation of Personalized Medicine Diagnostics in Cancer
07.3 Global Personalized Medicine Diagnostics Market in Microbiology
Market Size and Forecast
07.4 Global Personalized Medicine Diagnostics Market in Cardiovascular Diseases
Market Size and Forecast
Key Market Segmentation of Personalized Medicine Diagnostics in Cardiovascular Diseases
07.5 Global Personalized Medicine Diagnostics Market in Coagulation Therapy
Market Size and Forecast
Key Market Segmentation of Personalized Medicine Diagnostics in Coagulation Therapy
07.6 Global Personalized Medicine Diagnostics Market in Infectious Diseases
Market Size and Forecast
Key Market Segmentation of Personalized Medicine Diagnostics in Infectious Diseases
07.7 Global Personalized Medicine Diagnostics Market in Organ Transplant Management
Market Size and Forecast
07.8 Global Personalized Medicine Diagnostics Market in Psychiatric Disorders
Market Size and Forecast
07.9 Global Personalized Medicine Diagnostics Market in Blood Transfusion
Market Size and Forecast
07.10 Five Forces Analysis
08. Geographical Segmentation
09. Key Leading Countries
USA
Germany
Japan
10. Vendor Landscape
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Key Vendor Analysis
17.1 Abbott Laboratories
Business Overview
Key Information
SWOT Analysis
17.2 AstraZeneca plc
Business Overview
Key Information
SWOT Analysis
17.3 Becton Dickinson and Company
Business Overview
Key Information
SWOT Analysis
17.4 bioMerieux SA
Business Overview
Key Information
SWOT Analysis
17.5 Novartis AG
Business Overview
Key Information
SWOT Analysis
17.6 Roche Holding AG
Business Overview
Key Information
SWOT Analysis
18. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Personal Medicine Diagnostics Market 2012-2016 (US$ million)
Exhibit 3: Global Personalized Medicine Diagnostics Market by Segmentation
Exhibit 4: Global Personalized Medicine Diagnostics Market by Segmentation 2012
Exhibit 5: Global Personalized Medicine Diagnostics Market in Diabetes 2012-2016 (US$ million)
Exhibit 6: Global Personalized Medicine Diagnostics Market in Diabetes by Segmentation
Exhibit 7: Global Personalized Medicine Diagnostics Market in Diabetes by Segmentation 2012
Exhibit 8: Global Personalized Medicine Diagnostics Market in Diabetes by Segmentation 2012-2016
Exhibit 9: Global Personal Medicine Diagnostics Market in Blood Glucose Monitoring 2012-2016 (US$ million)
Exhibit 10: Global Personal Medicine Diagnostics Market in HbA1c Monitoring 2012-2016 (US$ million)
Exhibit 11: Global Personalized Medicine Diagnostics Market in Cancer 2012-2016 (US$ million)
Exhibit 12: Global Personalized Medicine Diagnostics Market in Diabetes by Segmentation
Exhibit 13: Global Personalized Medicine Diagnostics Market in Cancer by Segmentation 2012
Exhibit 14: Global Personal Medicine Diagnostics Market in Pharmacodiagnostic Histology 2012-2016 (US$ million)
Exhibit 15: Global Personal Medicine Diagnostics Market in Flow Cytometry 2012-2016 (US$ million)
Exhibit 16: Global Personal Medicine Diagnostics Market in Tumor Markers 2012-2016 (US$ million)
Exhibit 17: Global Personal Medicine Diagnostics Market in HPV 2012-2016 (US$ million)
Exhibit 18: Global Personal Medicine Diagnostics Market in Molecular Assays 2012-2016 (US$ million)
Exhibit 19: Global Personal Medicine Diagnostics Market in Circulating Tumor Cells 2012-2016 (US$ million)
Exhibit 20: Global Personalized Medicine Diagnostics Market in Microbiology 2012-2016 (US$ million)
Exhibit 21: Global Personalized Medicine Diagnostics Market in Cardiovascular Diseases 2012-2016 (US$ million)
Exhibit 22: Global Personalized Medicine Diagnostics Market in Cardiovascular Diseases by Segmentation
Exhibit 23: Global Personalized Medicine Diagnostics Market in Cardiovascular Diseases by Segmentation 2012
Exhibit 24: Global Personalized Medicine Diagnostics Market in Cardiovascular Diseases by Segmentation 2012-2016
Exhibit 25: Global Personal Medicine Diagnostics Market in Immunoassay Cardiac Markers (US$ million)
Exhibit 26: Global Personal Medicine Diagnostics Market in Cardiac Risk Markers (US$ million)
Exhibit 27: Global Personal Medicine Diagnostics Market in Molecular Cardiac Markers (US$ million)
Exhibit 28: Global Personalized Medicine Diagnostics Market in Coagulation Therapy 2012-2016 (US$ million)
Exhibit 29: Global Personalized Medicine Diagnostics Market in Coagulation Therapy by Segmentation
Exhibit 30: Global Personalized Medicine Diagnostics Market in Coagulation Therapy by Segmentation 2012
Exhibit 31: Global Personalized Medicine Diagnostics Market in Coagulation Therapy by Segmentation 2012-2016
Exhibit 32: Global Personal Medicine Diagnostics Market in Routine Coagulation (US$ million)
Exhibit 33: Global Personal Medicine Diagnostics Market in Molecular Coagulation (US$ million)
Exhibit 34: Global Personalized Medicine Diagnostics Market in Infectious Diseases 2012-2016 (US$ million)
Exhibit 35: Global Personalized Medicine Diagnostics Market in Infectious Diseases by Segmentation
Exhibit 36: Global Personalized Medicine Diagnostics Market in Infectious Diseases by Segmentation 2012
Exhibit 37: Global Personal Medicine Diagnostics Market in Viral Load HBV (US$ million)
Exhibit 38: Global Personal Medicine Diagnostics Market in Molecular HAI (US$ million)
Exhibit 39: Global Personal Medicine Diagnostics Market in Sepsis Immunoassay (US$ million)
Exhibit 40: Global Personal Medicine Diagnostics Market in CD4 HIV (US$ million)
Exhibit 41: Global Personal Medicine Diagnostics Market in Viral Load HIV (US$ million)
Exhibit 42: Global Personal Medicine Diagnostics Market in Viral Load HCV (US$ million)
Exhibit 43: Global Personal Medicine Diagnostics Market in MDR-TB (US$ million)
Exhibit 44: Global Personalized Medicine Diagnostics Market in Organ Transplant Management 2012-2016 (US$ million)
Exhibit 45: Global Personalized Medicine Diagnostics Market in Psychiatric Disorders 2012-2016 (US$ million)
Exhibit 46: Global Personalized Medicine Diagnostics Market in Blood Transfusion 2012-2016 (US$ million)
Exhibit 47: Global Personalized Medicine Diagnostics Market by Geographical Segmentation 2012
Exhibit 48: Business Segmentation of Abbott Laboratories
Exhibit 49: Business Segmentation of AstraZeneca plc
Exhibit 50: Business Segmentation of Becton Dickinson and Company
Exhibit 51: Business Segmentation of bioMerieux SA
Exhibit 52: Business Segmentation of Novartis AG
Exhibit 53: Business Segmentation of Roche Holding AG
Exhibit 54: Roche Pharmaceuticals Segment Sales in FY2012
Exhibit 55: Roche Diagnostics Segment Sales in FY2012

FEATURED COMPANIES

  • 20/20 GeneSystems Inc.
  • AltheaDx Inc.
  • BG Medicine Inc.
  • CombiMatrix Corp.
  • Genomic Health Inc.
  • MDxHealth SA
  • MORE

Commenting on the report, an analyst from the team said: “One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.”

According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed.

Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries.

The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are 20/20 GeneSystems Inc., Accumetrics Inc., AdvanDx Inc., Affymetrix Inc., Agilent Technologies Inc., Almac Group Ltd., AltheaDx Inc., Ambry Genetics Corp., Amgen Inc., Arrayit Corp., AssureRx Health Inc., Autogenomics Inc., BG Medicine Inc., Biocare Medical LLC, Biocartis SA, Biocept Inc., BioCurex Inc., Biodesix Inc., Bio-Reference Laboratories Inc., bioMerieux SA, CombiMatrix Corp., Corgenix Medical Corp., DxTerity Diagnostics Inc., Enzo Biochem Inc., Epigenomics AG, Euroimmun AG, GE Healthcare, Genomic Health Inc., Illumina Inc., Interleukin Genetics Inc., Johnson & Johnson, Knome Inc., Lab21 Ltd., Life Technologies Corp., MDxHealth SA, Myriad Genetics Inc., Nanosphere Inc., Pathway Genomics Corp., Power3 Medical Products Inc., Quest Diagnostics Inc., Response Genetics Inc., Rosetta Genomics Ltd., Sequenom Inc., Trovagene Inc., Vermillion Inc., Viracor-IBT Laboratories Inc.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Abbott Laboratories
- Agilent Technologies Inc.
- Becton Dickinson and Company
- bioMerieux SA
- Illumina Inc.
- and Roche Holding AG.
- 20/20 GeneSystems Inc.
- Accumetrics Inc.
- AdvanDx Inc.
- Affymetrix Inc.
- Almac Group Ltd.
- AltheaDx Inc.
- Ambry Genetics Corp.
- Amgen Inc.
- Arrayit Corp.
- AssureRx Health Inc.
- Autogenomics Inc.
- BG Medicine Inc.
- Biocare Medical LLC
- Biocartis SA
- Biocept Inc.
- BioCurex Inc.
- Biodesix Inc.
- Bio-Reference Laboratories Inc.
- CombiMatrix Corp.
- Corgenix Medical Corp.
- DxTerity Diagnostics Inc.
- EnzoBiochem Inc.
- Epigenomics AG
- Euroimmun AG
- GE Healthcare
- Genomic Health Inc.
- Interleukin Genetics Inc.
- Johnson & Johnson
- Knome Inc.
- Lab21 Ltd.
- Life Technologies Corp.
- MDxHealth SA
- Myriad Genetics Inc.
- Nanosphere Inc.
- Pathway Genomics Corp.
- Power3 Medical Products Inc.
- Quest Diagnostics Inc.
- Response Genetics Inc.
- Rosetta Genomics Ltd.
- Sequenom Inc.
- Trovagene Inc.
- Vermillion Inc.
- and Viracor-IBT Laboratories Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos